Protein kinase C and the development of diabetic vascular complications

Diabetic Medicine

Volumn 18, Issue 12, 2001, Pages 945-959

  Way, K J ^a   Katai, N ^a   King, G L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

Author keywords

Diabetes mellitus; LY333531; PKC isoforms; PKC ; Protein kinase C (PKC); Vitamin E

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 3 [2 [4 (4,4' DIFLUOROBENZHYDRYLIDENE)PIPERIDINO]ETHYL] 2,3 DIHYDRO 2 THIOXO 4(1H) QUINAZOLINONE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALPHA TOCOPHEROL; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; UNCLASSIFIED DRUG; WAY 151003;

BASEMENT MEMBRANE; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; CARDIOMYOPATHY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STRUCTURE; ENZYME SUBUNIT; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HEART DISEASE; HUMAN; HYPERGLYCEMIA; KIDNEY DISEASE; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHY; NONHUMAN; RETINOPATHY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOMYOPATHIES; DIABETIC ANGIOPATHIES; ENZYME INHIBITORS; HUMANS; INDOLES; ISOENZYMES; MALEIMIDES; PROTEIN KINASE C; SIGNAL TRANSDUCTION;

EID: 0035669720     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0742-3071.2001.00638.x     Document Type: Review

References (167)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
3. Aldose reductase inhibitors: The end of an era or the need for different trial designs?
4. Aldose reductase in glucose toxicity: A potential target for the prevention of diabetic complications
5. Negative consequences of glycation
6. RAGE: A new target for the prevention and treatment of the vascular and inflammatory complications of diabetes
7. Recent progress in advanced glycation end products and diabetic complications
8. Advanced glycation end-products: A review
9. Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II)
10. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm
11. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes
12. Protein kinase C activation and the development of diabetic complications
13. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus
14. Identification of PKC-isoform-specific biological actions using pharmacological approaches
15. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
16. Multiple pathways control protein kinase C phosphorylation
17. The potential for isoenzyme-selective modulation of protein kinase C
18. Signal transduction by protein kinase C in mammalian cells
19. The sevenfold way of PKC regulation
20. The extended protein kinase C superfamily
21. Regulation of protein kinase C
22. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation
23. Localization of protein kinase C isozymes in cardiac myocytes
24. Anchoring proteins for protein kinase C. A means for isozyme selectivity
25. Pharmacologic modulation of protein kinase C isozymes: The role of RACKs and subcellular localisation
26. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia
27. Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues
28. Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications
29. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
30. Induction of endothelin-1 expression by glucose: An effect of protein kinase C activation
31. Vitamin E normalizes diacylglycerol-protein kinase C activation induced by hyperglycemia in rat vascular tissues
32. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alphatocopherol
33. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures
34. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium
35. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor
36. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation
37. Diabetes-induced metabolic abnormalities in myocardium: Effect of antioxidant therapy
38. Changes in cardiac protein kinase C activities and isozymes in streptozotocin-induced diabetes
39. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart
40. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels
41. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose
42. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes
43. Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: An alteration not due to hyperglycemia
44. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo
45. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels
46. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine
47. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats
48. Calcium-dependent protein kinase activity is decreased in diabetic rat sciatic nerve
49. Diminished specific activity of cytosolic protein kinase C in sciatic nerve of streptozocin-induced diabetic rats and its correction by dietary myo-inositol
50. Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases
51. Alpha-lipoic acid: Effect on glucose uptake, sorbitol pathway, and energy metabolism in experimental diabetic neuropathy
52. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats
53. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways
54. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats
55. Altered expression and subcellular localization of diacylglycerol-sensitive protein kinase C isoforms in diabetic rat glomerular cells
56. Translocation of protein kinase C alpha and zeta in rat glomerular mesangial cells cultured under high glucose conditions
57. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E
58. Changes in protein kinase C in early cardiomyopathy and in gracilis muscle in the BB/Wor diabetic rat
59. Experimental diabetes is associated with functional activation of protein kinase C epsilon and phosphorylation of troponin I in the heart, which are prevented by angiotensin II receptor blockade
60. Alpha, beta I, beta II, delta, and epsilon protein kinase C isoforms and compound activity in the sciatic nerve of normal and diabetic rats
61. Protein kinase C isozyme expression in sciatic nerves and spinal cords of experimentally diabetic rats
62. The molecular heterogeneity of protein kinase C and its implications for cellular regulation
63. The family of protein kinase C for signal transduction
64. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
65. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy
66. Retinal circulatory abnormalities in type 1 diabetes
67. Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an alpha-glucosidase inhibitor
68. Retinal blood flow in normal and diabetic dogs
69. Retinal blood flow changes in type I diabetes. A long-term follow-up study
70. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: A potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy
71. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats
72. Diabetes-induced vascular dysfunction in the retina: Role of endothelins
73. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1
74. The in vivo effect of endothelins on retinal circulation in nondiabetic and diabetic rats
75. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products
76. Abnormally increased glomerular filtration rate in short-term insulin-treated diabetic subjects
77. Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics
78. Glomerular hemodynamics in experimental diabetes mellitus
79. Early functional and morphological changes in diabetic nephropathy
80. Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus
81. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to the hyperfiltration of early diabetes
82. Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells
83. Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats
84. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy
85. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration
86. Enhanced expression of inducible nitric oxide synthase in murine macrophages and glomerular mesangial cells by elevated glucose levels: Possible mediation via protein kinase C
87. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response
88. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy
89. Effects of the diacylglycerol complexing agent, cremophor, on nerve-conduction velocity and perfusion in diabetic rats
90. Glomerular matrix proteins in nodular glomerulosclerosis in association with light chain deposition disease and diabetes mellitus
91. The immunohistopathology of glomerular antigens. II. The glomerular basement membrane, actomyosin, and fibroblast surface antigens in normal, diseased, and transplanted human kidneys
92. ECM gene expression and its modulation by insulin in diabetic rats
93. Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells
94. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells
95. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells
96. PKC and high glucose stimulate collagen alpha 1 (IV) transcriptional activity in a reporter mesangial cell line
97. Characteristics and mechanisms of high-glucose-induced overexpression of basement membrane components in cultured human endothelial cells
98. Regulation of fibronectin and laminin synthesis by retinal capillary endothelial cells and pericytes in vitro
99. Fibronectin overexpression in retinal microvessels of patients with diabetes
100. Fibronectin, laminin, vitronectin and their receptors at newly-formed capillaries in proliferative diabetic retinopathy
101. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta
102. mRNA expression of growth factors in glomeruli from diabetic rats
103. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse
104. Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy
105. Renal TGF-beta regulation in spontaneously diabetic NOD mice with correlations in mesangial cells
106. Transforming growth factor-beta 1 enhances glomerular collagen synthesis in diabetic rats
107. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy
108. Transcriptional activation of matrix genes by transforming growth factor beta 1 in mesangial cells
109. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta
110. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1
111. The 260-kDa transforming growth factor (TGF) -beta binding protein in rat glomeruli is a complex comprised of 170- and 85-kDa TGF-beta binding proteins
112. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice
113. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells
114. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis
115. Connective tissue growth factor: What's in a name?
116. Role of protein kinase C in insulin's regulation of c-fos transcription
117. The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes
118. The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites
119. Characterization of site-specific mutants altered at protein kinase C beta 1 isozyme autophosphorylation sites
120. Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: A potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia
121. Serum stimulation of fibronectin gene expression appears to result from rapid serum-induced binding of nuclear proteins to a cAMP response element
122. Characterization of a novel promoter structure and its transcriptional regulation of the murine laminin B1 gene
123. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes. Prevention by aldose reductase inhibitors and castration
124. Increased endothelial albumin permeability mediated by protein kinase C activation
125. Adenylate cyclase and protein kinase C mediate opposite actions on endothelial junctions
126. Protein kinase C phosphorylates caldesmon77 and vimentin and enhances albumin permeability across cultured bovine pulmonary artery endothelial cell monolayers
127. The role of phosphorylation and limited proteolytic cleavage of talin and vinculin in the disruption of focal adhesion integrity
128. Vinculin, a cytoskeletal substrate of protein kinase C
129. A tumor promoter induces rapid and coordinated reorganization of actin and vinculin in cultured cells
130. Protein kinase C beta 1 overexpression augments phorbol ester-induced increase in endothelial permeability
131. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha
132. Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues
133. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
134. Structure-function relationships of cation binding in the Na(+)/K(+)-ATPase
135. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications
136. Altered retinal metabolism in diabetes II. Measurement of sodium-potassium ATPase and total sodium and potassium in individual retinal layers
137. Banting lecture 1986. Does a common mechanism induce the diverse complications of diabetes?
138. Protein kinase C agonists acutely normalize decreased ouabain-inhibitable respiration in diabetic rabbit nerve. Implications for (Na,K)-ATPase regulation and diabetic complications
139. Identification of the mechanism for the inhibition of Na(+),K(+)-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2
140. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease?
141. Evidence for cardiomyopathy in familial diabetes mellitus
142. Increased rat myocardial type VI collagen in diabetes mellitus and hypertension
143. Overexpression of fibronectin induced by diabetes or high glucose: Phenomenon with a memory
144. Diabetes mellitus induces changes in cardiac myosin of the rat
145. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy
146. Troponin I phosphorylation in heart homogenate from diabetic rat
147. Protein kinase C phosphorylation of cardiac troponin I or troponin T inhibits Ca2(+)-stimulated actomyosin MgATPase activity
148. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy
149. In vivo phosphorylation of cardiac troponin I by protein kinase Cbeta2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts
150. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation
151. Protein kinase C isoform diversity in the heart
152. PKCε activation induces dichotomous cardiac phenotypes and modulates PKCε-RACK interactions and RACK expression
153. Role of protein kinase C-ε in hypertrophy of cultured neonatal rat ventricular myocytes
154. Inhibition of cell proliferation by alpha-tocopherol. Role of protein kinase C
155. Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications?
156. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway
157. Vitamin E suppresses diacylglycerol (DAG) level in thrombin-stimulated endothelial cells through an increase of DAG kinase activity
158. d-Alpha-tocopherol prevents the hyperglycemia induced activation of diacylglycerol (DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an increase of DAG kinase activity
159. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes
160. Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy
161. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
162. (S)-13-[(dimethylamino)methyl]-10,11,14, 15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: Isozyme selective inhibitors of protein kinase C beta
163. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats
164. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531
165. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats
166. Protein kinase C β-selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes
167. Amelioration of abnormal retinal hemodynamics by a protein kinase C β selective inhibitor (LY333531) in patients with diabetes: Results of a Phase 1 safety and pharmacodynamic clinical trial